Cellular Biomedicine Group Announces Annual General Meeting of Stockholders
August 01 2016 - 8:30AM
Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the
“Company”), a clinical-stage biomedicine firm engaged in the
development of effective stem cell therapies for degenerative
diseases and immunotherapies for cancer, today announced that the
Annual General Meeting of Stockholders will be held on Friday,
September 9, 2016. The meeting will be held at the Company’s
office at 19925 Stevens Creek Blvd., Suite 100, Cupertino,
California 95014 at 9:00 a.m. PDT. Stockholders of record as
of July 26, 2016, the record date for the meeting, are authorized
and instructed to vote in the manner directed in the proxy
materials.
A stockholder, once having received his/her
proxy notice and access card, may view the proxy statement and
related materials online or request a printed copy
at www.iproxydirect.com/CBMG. Stockholders may vote online, by
mail or by phone, according to the instructions on the proxy, no
later than 11:59pm, Thursday, September 8, 2016, EDT. If your
shares are held in the name of a bank, broker or other nominee,
please check with your bank, broker or nominee and follow the
voting instructions it provides. Please send an email to
sarah.kelly@cellbiomedgroup.com if you have questions about
this proxy voting or have not received your proxy notice card by
post or by email.
About Cellular Biomedicine Group Cellular
Biomedicine Group, Inc. develops proprietary cell therapies for the
treatment of certain degenerative and cancerous diseases. Our
developmental stem cell and Immuno-Oncology projects are the result
of research and development by scientists and doctors
from China and the United States. Our GMP facilities
in China, consisting of nine independent cell production lines, are
designed, certified and managed according to U.S. standards.
To learn more about CBMG, please visit:
www.cellbiomedgroup.com
Forward-Looking Statements Statements in this
press release relating to plans, strategies, trends, specific
activities or investments, and other statements that are not
descriptions of historical facts may be forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995, Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended.
Forward-looking information is inherently subject to risks and
uncertainties, and actual results could differ materially from
those currently anticipated due to a number of factors, which
include risks inherent in doing business, trends affecting the
global economy, including the devaluation of the RMB by China in
August 2015 and other risks detailed from time to time in CBMG’s
reports filed with the Securities and Exchange Commission,
quarterly reports on form 10-Q, current reports on form 8-K and
annual reports on form 10-K. Forward-looking statements may be
identified by terms such as "may," "will," "expects," "plans,"
"intends," "estimates," "potential," or "continue," or similar
terms or the negative of these terms. Although CBMG believes the
expectations reflected in the forward-looking statements are
reasonable, they cannot guarantee that future results, levels of
activity, performance or achievements will be obtained. CBMG does
not have any obligation to update these forward-looking statements
other than as required by law.
Contacts:
Sarah Kelly
Director of Corporate Communications, CBMG
+1 650 566-5064
sarah.kelly@cellbiomedgroup.com
Vivian Chen
Managing Director Investor Relations, Grayling
+1 347 481-3711
vivian.chen@grayling.com
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From Sep 2023 to Sep 2024